The PDGF/PDGFR pathway as a drug target

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Platelet-derived growth factors (PDGF) regulate cell proliferation, survival, and migration, particularly in mesenchymal cells.
• Dysregulated PDGF signaling is implicated in numerous diseases, including cancer, fibrosis, neurological disorders, and atherosclerosis.
• Abnormalities in the PDGF pathway involve PDGFR overexpression, mutations, or translocations.

Purpose of the Study:

• To review current therapeutic strategies targeting PDGF signaling.
• To examine existing drugs that interfere with PDGF-receptor interactions.
• To discuss clinical successes and ongoing challenges in PDGF-targeted therapies.

Main Methods:

• Literature review of therapeutic approaches for PDGF pathway interference.
• Analysis of drug development strategies including aptamers, ligand traps, antibodies, and small molecules.
• Evaluation of clinical data for PDGF-targeted therapies.

Main Results:

• Various strategies exist to inhibit PDGF signaling, including targeting ligand-receptor binding and PDGFR activity.
• Approved and investigational drugs utilize diverse mechanisms like aptamers, antibodies, and kinase inhibitors.
• Clinical applications show promise but face challenges in efficacy and specificity.

Conclusions:

• Targeting PDGF signaling offers a promising therapeutic avenue for multiple diseases.
• Continued research is needed to overcome challenges and optimize PDGF-targeted treatments.
• Development of specific and effective inhibitors remains a key focus for clinical success.